Irisin Expression and Gene Polymorphism in Type II Diabetic Patients With and Without CAD (CAD)

February 27, 2024 updated by: Amera Morad Foad, Sohag University

Serum Irisin Level & FDNC5 Genetic Polymorphism Can Predict the Presence &Severity of Coronary Artery Disease in Patients With Type II DM?

This is an observertional study aimed at Study the association between the level of irisin expression and (Fibronectin Type III Domain Containing 5 (FDNC5) gene polymorphism and the presence and severity of coronary artery disease in patients with Type II DM.

Study Overview

Status

Completed

Conditions

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Egypt
      • Sohag, Egypt
        • Sohag uniersity hosoital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

N/A

Sampling Method

Probability Sample

Study Population

type II diabetic patients with and without coronary artery disease in our center in sohag university hospital.

Description

Inclusion Criteria:

  • This study will include type II diabetic patients aged between 18 and 45 years old

Exclusion Criteria:

  1. Recent acute myocardial infarction.
  2. patients with Heart Failure
  3. Active infection
  4. End stage renal failure (GFR < 30 ml/min) or on dialysis
  5. Liver cell failure
  6. Athletes or having heavy muscular exercise in the previous 3 days

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Diseased
type II diabetic patients with documented coronary artery disease.
Control
type II diabetic patients without coronary artery disease.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Irisin level
Time Frame: 6 months
detect the serum level of irisin hormone by ELIZA in nanogram/decilitre(ng/dl)
6 months
FNDC5 Genotyping
Time Frame: 6 months
whether homogenetic or heterogenetic
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 20, 2021

Primary Completion (Actual)

August 30, 2022

Study Completion (Actual)

October 30, 2023

Study Registration Dates

First Submitted

July 3, 2021

First Submitted That Met QC Criteria

July 3, 2021

First Posted (Actual)

July 12, 2021

Study Record Updates

Last Update Posted (Estimated)

February 29, 2024

Last Update Submitted That Met QC Criteria

February 27, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Other Study ID Numbers

  • Soh-Med-21-06-20

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Irisin Gene Polymorphism in Type II Diabetic Patients

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe